Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Akorn has signed a commercial manufacturing supply agreement with GeneraMedix, a company that develops, markets and sells generic injectable pharmaceutical products.
Subscribe to our email newsletter
The agreement will allow Akorn to manufacture injectable products in finished dosage form for GeneraMedix, who will market these products under the GeneraMedix label. The agreement includes products currently available from Akorn, as well as selected injectable products from the Akorn internal product development pipeline.
“This partnership will allow us to expand our existing market share and increase our contract sales revenues. We believe that GeneraMedix and their executive management team have the experience and infrastructure to successfully market these generic products to the hospital and specialty pharmaceutical markets,” stated Arthur Przybyl, president and CEO of Akorn.
GenraMedix said they were pleased they were able to build on their injectable product portfolio as a result of the deal.
Akorn manufactures and markets sterile specialty pharmaceuticals. GenraMedix is a pharmaceutical company that provides its injectable generic products to the hospital and specialty markets.